An open label study of the effects of rituximab in neuromyelitis optica

By Bruce A.C. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant, C. Genain. Neurology, 2005

630 citations recorded by the source corpus.

Subfields: Neurology, Pathology and Forensic Medicine, Rheumatology

View Paper: https://www.semanticscholar.org/paper/a18ce254e4a783b864b73284db0164bb27e13a52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Stephen L. Hauser

In Pathology and Forensic Medicine

1. Jorge R. Oksenberg
2. Stephen L. Hauser

In Rheumatology

1. Stephen L. Hauser

Citations in the corpus

• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. (2006, background): “…administration of B cell-depleting antibodies, such as the humanized anti-CD20 monoclonal antibody Rituximab , is currently under evaluation in MS (Cree et al., 2005; Cross and Stark, 2005), and positive results from a phase 2 trial of Rituximab in relapsing-remitting MS were recently reported.”